Make an Inquiry
Accelerating Overactive Bladder Drug Development

Overactive bladder (OAB) presents a significant unmet medical need, impacting millions of individuals and challenging current standards of care. Ace Therapeutics is a specialized partner in the development of novel therapeutics targeting OAB, offering a comprehensive suite of preclinical drug development services that span target validation, lead optimization, and IND-enabling studies. Ace Therapeutics distinguishes itself through deep scientific expertise in urological disorders, integration of advanced in vitro and in vivo platforms, and rigorous adherence to global regulatory standards. Our multidisciplinary team leverages state-of-the-art technologies and translational models to generate robust, decision-driving data, enabling efficient progression from discovery to clinical candidate selection. With a focus on innovation and quality, Ace Therapeutics is committed to accelerating the development of effective OAB therapies. By combining scientific rigor with operational excellence, Ace Therapeutics empowers biopharmaceutical partners to advance breakthrough treatments that address the complexities of overactive bladder and improve patient outcomes.

What is Overactive BladderTargets for Overactive BladderDrug Discovery and Development ServicesWhy Choose Us

What is Overactive Bladder

Overactive bladder (OAB) is a common clinical syndrome characterized by urinary urgency, typically accompanied by increased daytime frequency and nocturia, with or without urge urinary incontinence, in the absence of infection or other obvious pathology. The etiology of OAB is multifactorial, involving abnormal detrusor muscle activity, heightened sensory nerve signaling, and altered central nervous system control of bladder function. Both neurogenic and idiopathic forms exist, with neurogenic OAB resulting from neurological conditions such as multiple sclerosis or spinal cord injury, while idiopathic OAB occurs without identifiable cause. Disruption of neural and myogenic pathways, as well as urothelial dysfunction, contribute to involuntary detrusor contractions during bladder filling. Clinically, OAB presents with a sudden, compelling urge to urinate, often leading to increased frequency, nocturia, and, in some cases, involuntary leakage (urge incontinence). Diagnosis is primarily clinical, relying on symptom assessment, exclusion of urinary tract infection or structural abnormalities, and use of tools such as bladder diaries and questionnaires. Urinalysis and, in select cases, urodynamic studies or imaging may be indicated. Management includes lifestyle modifications and pharmacotherapy. Medications such as antimuscarinics (e.g., solifenacin, tolterodine, darifenacin) and beta-3 adrenergic agonists (e.g., mirabegron, vibegron) are commonly used to reduce urgency and frequency and improve quality of life.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-1190389-15-1-vibegron-rec-inn-usan vibegron (Rec INN; USAN) 1190389-15-1 C26 H28 N4 O3 444.526
img-1035547-81-9-solifenacin-tartrate solifenacin tartrate 1035547-81-9 C23 H26 N2 O2 . C4 H6 O6 512.552
ATD-oxybutynin; oxybutynin-ATD
img-223673-61-8-mirabegron-prop-inn-usan mirabegron (Prop INN; USAN) 223673-61-8 C21 H24 N4 O2 S 396.506
img-286930-02-7-free-base286930-03-8-fesoterodine-fumarate-rec-innm-usan fesoterodine fumarate (Rec INNM; USAN) 286930-02-7 (free base); 286930-03-8 C26 H37 N O3 . C4 H4 O4 527.649
tamsulosin hydrochloride/tolterodine tartrate
img-170105-16-5-imidafenacin-rec-inn imidafenacin (Rec INN) 170105-16-5 C20 H21 N3 O 319.4
img-242478-38-2-solifenacin-succinate-rec-innm-usan solifenacin succinate (Rec INNM; USAN) 242478-38-2 C23 H26 N2 O2 . C4 H6 O4 480.553
img-133099-07-7-darifenacin-hydrobromide-rec-innm-usan-banm darifenacin hydrobromide (Rec INNM; USAN; BANM) 133099-07-7 C28 H30 N2 O2 . Br H 507.462
img-124937-51-5-free-base124937-52-6-tolterodine-tartrate-rec-innm-usan tolterodine tartrate (Rec INNM; USAN) 124937-51-5 (free base); 124937-52-6 C22 H31 N O . C4 H6 O6 475.574

Learn More

Targets for Overactive Bladder

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Acetylcholine
adrenoceptor beta 3 ADRB3
alpha1-Adrenoceptor (nonspecified subtype)
cholinergic receptor muscarinic 1 CHRM1
cholinergic receptor muscarinic 3 CHRM3
Muscarinic Acetylcholine Receptor (mAChR) (nonspecified subtype)
Acetylcholine Receptors (Nicotinic) (nAChR) (nonspecified subtype)
potassium voltage-gated channel subfamily Q member 1 KCNQ1
potassium voltage-gated channel subfamily E regulatory subunit 2 KCNE2
potassium voltage-gated channel subfamily E regulatory subunit 1 KCNE1

Overactive bladder (OAB) involves complex dysregulation of bladder storage and voiding, mediated by several key molecular targets. The most prominent among these are the muscarinic acetylcholine receptors—CHRM1 and CHRM3—which drive detrusor muscle contraction in response to cholinergic signaling. CHRM3, in particular, is the principal receptor subtype responsible for bladder contraction during micturition, while CHRM1 also contributes to cholinergic excitability and afferent signaling. On the inhibitory side, adrenoceptor beta 3 (ADRB3) is highly expressed in detrusor smooth muscle and mediates relaxation via the sympathetic nervous system by increasing intracellular cAMP. Additionally, phosphodiesterase 5A (PDE5A) regulates smooth muscle tone by hydrolyzing cGMP, with its inhibition promoting muscle relaxation through enhanced NO-cGMP signaling.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates overactive bladder drug discovery by providing robust, sensitive platforms to evaluate candidate compounds targeting muscarinic acetylcholine receptors. Utilizing radioligand binding, label-free biosensor, and fluorescence-based assays, we quantify ligand binding affinity, receptor activation, and downstream signaling. Key pharmacological parameters, including IC-50 and Ki, are measured to support lead compound selection and optimization. Our assays enable detailed profiling of compound potency and selectivity, guiding rational drug design. This comprehensive approach ensures reliable data for decision-making and reduces attrition, delivering high-value support for the development of effective overactive bladder therapies.

Cholinergic Receptor Muscarinic 1 Cholinergic Receptor Muscarinic 3

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the field of Overactive bladder therapeutics through specialized expertise and unwavering professionalism. Our team comprises experienced scientists and industry experts who possess deep knowledge in Overactive bladder research and drug development, ensuring that every project benefits from the highest level of insight and skill. We utilize advanced technology platforms and state-of-the-art facilities to deliver innovative preclinical solutions tailored to the unique challenges of Overactive bladder therapeutics. With a proven track record of reliability and success in preclinical drug development services, Ace Therapeutics is recognized for delivering results that consistently meet and exceed client expectations. We adhere to the strictest quality standards and maintain full regulatory compliance, ensuring that every stage of development is conducted with integrity and precision. Above all, Ace Therapeutics is committed to driving progress in Overactive bladder treatment, partnering with clients to bring safe and effective new therapies to patients in need. When you choose Ace Therapeutics, you are choosing a trusted partner dedicated to excellence, reliability, and meaningful scientific advancement.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Overactive Bladder (OAB)?

A: One of the primary challenges in preclinical OAB drug development is the lack of animal models that fully recapitulate the human pathophysiology of OAB. Additionally, the multifactorial nature of OAB, involving both neurogenic and myogenic components, makes it difficult to target a single pathway effectively. Our company addresses these challenges by employing a combination of validated in vivo and in vitro models, including bladder strip contractility assays and rodent models with induced detrusor overactivity, to provide comprehensive pharmacological profiling.

Q: What are the key regulatory considerations for preclinical development of OAB therapeutics?

A: Regulatory agencies such as the FDA and EMA require robust preclinical safety and efficacy data before advancing to clinical trials. For OAB drugs, this includes thorough pharmacodynamic and pharmacokinetic profiling, as well as safety pharmacology studies focusing on the urinary, cardiovascular, and central nervous systems. We ensure compliance by designing studies that adhere to ICH guidelines and by providing detailed documentation and data packages to facilitate regulatory submissions.

Q: What technical aspects should be considered when conducting preclinical research for OAB drug candidates?

A: Technical considerations include the selection of appropriate animal models, endpoints for efficacy (such as micturition frequency and bladder capacity), and reliable biomarkers. It is also important to assess off-target effects, particularly those affecting the central nervous system and cardiovascular system, due to the systemic distribution of many OAB drugs. Our team utilizes advanced telemetry, urodynamic measurements, and molecular assays to generate high-quality, reproducible data.

Q: What are the typical timeline and cost considerations for preclinical development of OAB drugs?

A: Preclinical development for OAB drugs typically spans 12 to 24 months, depending on the complexity of the compound and the breadth of required studies. Costs can vary significantly, ranging from $1 million to $5 million, influenced by the number of animal models, the extent of safety and efficacy testing, and regulatory requirements. Our company offers scalable study designs and transparent budgeting to help clients manage timelines and costs efficiently.

Q: What are the critical success factors in preclinical drug development for OAB?

A: Success in preclinical OAB drug development hinges on early identification of lead compounds with favorable efficacy and safety profiles, the use of predictive and translational animal models, and proactive risk assessment for off-target effects. Additionally, clear communication with regulatory agencies and robust data packages are essential for smooth progression to clinical trials. Our expertise in OAB pharmacology, coupled with a collaborative approach, ensures that these critical factors are addressed throughout the preclinical process.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.